Our lead product for severe pneumonia, plasma gelsolin, has application for COVID19.

Chief Operating Officer, Valerie Ceva, MBA

Valerie Ceva is the Chief Operating Officer, bringing to BioAegis a record of accomplishments in life science business development, strategic consulting and global venture capital transactions.

Prior to BioAegis, Ms. Ceva focused on emerging technology, supporting venture capital firms with investment strategy development and implementation and early stage companies in business model development, venture capital acquisition and operational execution, as a management consulting partner at The Strategic Choice and VentureWorks, LLC. Ms. Ceva’s work included several long-term projects such as: creation of a vaccine/diagnostic company and the development and execution of a new strategy for a top tier Private Equity firm. Ms. Ceva was a VP at I-TRAX.COM, Inc., a disease management application service provider, during its expansion/commercialization stage and IPO.

Prior to this, Ms. Ceva held executive positions at Novartis in Business Strategy, US and Corporate Business Development, Managed Care Marketing and Sales, as well as Venture Manager at Accel Partners. Ms. Ceva spearheaded some of Novartis’ most critical capability improvement initiatives including a reorganization and turnaround for the generic division, developing the company’s first lifecycle management strategy, leading post-merger integration initiatives.

Ms. Ceva has an MBA from University of Chicago and a BS in Biology from Bucknell University.